For example, Hou et al. showed significantly shorter median PFS (6.5 vs. 14 months, p = 0.025) and median overall survival (OS, 28 vs. 52 months, p = 0.023) in advanced NSCLC patients with the TP53 co-mutations treated with the first-generation TKIs (gefitinib, erlotinib, and icotinib) with respect to the patients with the wild-type TP53 [56]. Here, TP53 is linked to non-small cell lung carcinoma.